Overview

ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ambrisentan